Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis
- Conditions
- Neuroendocrine Tumors
- Interventions
- Other: Metastasized intestinal NET
- Registration Number
- NCT02646644
- Lead Sponsor
- University Medical Center Groningen
- Brief Summary
In an individual cancer patient extensive genetic and phenotypic variation exists between and within tumor lesions. Tumour load in NET patients can be measured with fluorine-18-L-dihydroxyphenylalaninepositron emission tomography (18F-DOPA-PET) scan.
This aim of the study is to investigate heterogeneity between tumor lesions within patients with intestinal NET by determining the differences in tracer uptake measured on a 18F- DOPA-PET scan retrospectively.
- Detailed Description
In an individual cancer patient extensive genetic and phenotypic variation exists between and within tumor lesions. Tumour load in NET patients can be measured with fluorine-18-L-dihydroxyphenylalanine positron emission tomography (18F-DOPA-PET) scan.
This aim of the study is to investigate heterogeneity between tumor lesions within patients with intestinal NET by determining the differences in tracer uptake measured on a 18F- DOPA-PET scan in retrospect.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 38
- age ≥18 years
- diagnosis of intestinal NET diagnosed by a dedicated NET specialist
- more than one positive lesion on the 18F-DOPA-PET scan.
- available CT-scan within 6 months before or after the 18F-DOPA-PET-scan.
- no clinical data available at the UMCG, besides the results of the DOPA PET scan.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Metastasized intestinal NET Metastasized intestinal NET We will select the 18F- DOPA-PET scans conducted in the Universtiy Medical Center of Groningen (UMCG) of adult patients with a metastasized intestinal NET between February 2014 until November 2015. Only patients of whose clinical data are available within the UMCG are included.
- Primary Outcome Measures
Name Time Method tracer uptake in tumor lesions within patients with intestinal NET at the day of scan The difference in tracer uptake of tumor lesions within patients with intestinal NET measured on a 18F- DOPA-PET scan.
- Secondary Outcome Measures
Name Time Method tracer uptake in tumor lesions within patients with intestinal NET adjusted for uptake of background organ at the day of scan The difference in tracer uptake of tumor lesions adjusted for uptake of background organ within patients with intestinal NET measured on a 18F- DOPA-PET scan.
Trial Locations
- Locations (1)
University Medical Center Groningen
🇳🇱Groningen, Netherlands